Move to topTop
December 12, 2016

TOKYO, JAPAN - Dec. 12, 2016 - Terumo Corporation (TSE: 4543) announced today that it has formulated its 5-year Mid- to Long-term Growth Strategy starting from April, 2017. As a global corporation with Japanese origins, we will achieve profitable and sustainable growth by executing the following strategies in a ten-year perspective.

Mid- to Long-term Growth Strategy

  1. . Win in selected strategic markets
    • Select growing segments and segments where Terumo owns a competitive advantage
    • oncentrate on intervention, neurovascular, D&D, and therapeutic apheresis
  2. . Offer comprehensive value in Japan
    • Leverage leading position and pursue growth opportunities
  3. Accelerate innovation
    • Contribute to future of healthcare with significant social impact
    • Advance core technologies and gain new technologies

Management Indicators for the Next Five Years

(Plan FX rate: USD=105 JPY, EUR=115 JPY)

Growth: Faster revenue growth than market growth
  High single-digit growth in revenue
Profitability: Faster profit growth than revenue growth
  Double-digit growth in profit*
  Adjusted EPS** 270 - 300 yen by 2021
Efficiency: Maintain ROE 10%+***
  • *

    Adjusted operating income (IFRS)

  • **

    Adjusted items: Intangible asset derived from acquisition, one time acquisition expense, impairment, gain/loss from sales of stocks and others

  • ***

    Excluding foreign currency translation adjustment balance related to the assets from acquisition included in net assets

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.